drugset / Trial / NCT00261313

ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer

NCT00261313

Phase 2 Completed 80 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a study of dose dense doxorubicin/cyclophosphamide (AC) followed by paclitaxel (Taxol; T) with pegfilgrastim (Neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.

Timeline

Start
2005-12
Primary completion
2007-06
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Background Darbepoetin alfa Protein / enzyme biologic 300 ug
Background Pegfilgrastim Protein / enzyme biologic 6 mg

Indications